Clinical Trial Update: Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation [NA]

View source ↗

Summary

The clinical trial evaluating FDG-PET/CT scans to predict response in stage IIIA non-small cell lung cancer during chemoradiation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stage Iiia Non-small Cell Lung Cancer

Drugs mentioned

• Fludeoxyglucose F-18 (Fludeoxyglucose F-18)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Stage IIIA Non-small Cell Lung Cancer | NA | Status: WITHDRAWN